Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873883 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
A Phase 1 study, sponsored by iTeos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT03873883: Completed Phase 1 study, sponsored by iTeos Therapeutics.
NCT03873883 is a Phase 1 study that has completed, run by iTeos Therapeutics. The registered enrollment target is 119 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03873883, a Phase 1 study, has completed, sponsored by iTeos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.
Primary Outcome
To define the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) of EOS100850 in patients receiving EOS100850
Interventions
- DRUG Pembrolizumab
- DRUG Chemotherapy
- DRUG EOS100850
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2019-02-05 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 1 |
What the finished NCT03873883 record still lists
NCT03873883 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03873883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03873883 about?
NCT03873883 is a clinical study titled "First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer". Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Par...
What is the current status of trial NCT03873883?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2019-02-05. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT03873883?
The interventions under investigation include: Pembrolizumab (DRUG), Chemotherapy (DRUG), EOS100850 (DRUG).
Who is sponsoring clinical trial NCT03873883?
This trial is sponsored by iTeos Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03873883's enrollment target sits among peer trials
119 498th of 2000 higher than 1,502 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI